The ASSOCIATE study investigators have reported that the If current inhibitor, ivabradine, is safe, improves exercise performance, and delays the development of ischemia in patients with chronic stable angina being treated with atenolol. Ivabradine should be considered in the medical management of symptom-limited patients with angina, when heart rate is suboptimally controlled.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Gating mechanism of hyperpolarization-activated HCN pacemaker channels
Nature Communications Open Access 17 March 2020
-
Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure
Acta Pharmacologica Sinica Open Access 14 December 2017
-
The Role of Ivabradine in the Management of Angina Pectoris
Cardiovascular Drugs and Therapy Open Access 30 July 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fox, K. et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur. Heart J. 27, 1341–1381 (2006).
Kannel, W. B. & Feinleib, M. Natural history of angina pectoris in the Framingham study. Prognosis and survival. Am. J. Cardiol. 29, 154–163 (1972).
Gibbons, R. J. et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J. Am. Coll. Cardiol. 41, 159–168 (2003).
Tardif, J. C., Ponikowski, P. & Kahan, T. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur. Heart J. 30, 540–548 (2009).
Fox, K. M. Exercise heart rate/ST segment relation. Perfect predictor of coronary disease. Br. Heart J. 48, 309–310 (1982).
Gislason, G. H. et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur. Heart J. 27, 1153–1158 (2006).
Fox, K. M., Mulcahy, D., Findlay, I., Ford, I. & Dargie, H. J. The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur. Heart J. 17, 96–103 (1996).
Klein, W. W., Jackson, G. & Tavazzi, L. Efficacy of monotherapy compared with combined antianginal drugs in the treatment of chronic stable angina pectoris: a meta-analysis. Coron. Artery Dis. 13, 427–436 (2002).
Knight, C. J. & Fox, K. M. Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Centralised European Studies in Angina Research (CESAR) Investigators. Am. J. Cardiol. 81, 133–136 (1998).
Borer, J. S., Fox, K., Jaillon, P. & Lerebours, G. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107, 817–823 (2003).
Tardif, J. C., Ford, I., Tendera, M., Bourassa, M. G. & Fox, K. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur. Heart J. 26, 2529–2536 (2005).
Boden, W. E. et al. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med. 356, 1503–1516 (2007).
Daly, C. A. et al. The initial management of stable angina in Europe, from the Euro Heart Survey: a description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. Eur. Heart J. 26, 1011–1022 (2005).
Chaitman, B. R. et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291, 309–316 (2004).
Fox, K., Ford, I., Steg, P. G., Tendera, M. & Ferrari, R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372, 807–816 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R. de Silva has received speakers' bureau honoraria from Servier. K. M. Fox has acted as a Consultant for and has received speakers' bureau honoraria and research support from Servier.
Rights and permissions
About this article
Cite this article
de Silva, R., Fox, K. Ivabradine for treatment of stable angina pectoris. Nat Rev Cardiol 6, 329–330 (2009). https://doi.org/10.1038/nrcardio.2009.47
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2009.47
This article is cited by
-
Gating mechanism of hyperpolarization-activated HCN pacemaker channels
Nature Communications (2020)
-
Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure
Acta Pharmacologica Sinica (2018)
-
The Role of Ivabradine in the Management of Angina Pectoris
Cardiovascular Drugs and Therapy (2016)
-
Heart rate in ischemic heart disease. The innovation of ivabradine: More than pure heart rate reduction
Advances in Therapy (2010)